Pharnext (PNEXF) Stock Price, News & Analysis

Company Overview

Pharnext is a French biopharmaceutical company that historically focused on developing treatments for rare and neurodegenerative diseases. The company’s research was based on its “Pleotherapy” platform, which seeks to identify therapeutic combinations of existing medicines and optimize them for new medical uses.

Pharnext’s leading investigational product was PXT3003, a fixed-dose combination of baclofen, naltrexone and sorbitol developed for Charcot-Marie-Tooth disease type 1A, an inherited peripheral neuropathy. The company also evaluated other drug-repositioning programs for neurological conditions, although these programs remained at the development stage rather than being marketed products.

Pharnext was headquartered in France and primarily operated as a clinical-stage biotechnology company serving the international rare-disease research and development market. Following unsuccessful clinical development and financial difficulties, the company entered judicial liquidation proceedings in France in 2023, substantially limiting its ongoing corporate and research activities.

Key Stats

• Today's Range: $400.00 to $400.00
• 50-Day Range: $400.00 to $400.00
• 52-Week Range: $0.0001 to $0.0010
• Volume: 16,660 shs
• Average Volume: 433 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:PNEXF
• CIK: N/A
• Web: www.pharnext.com
• Phone: (314) 109-2230
• Fax: N/A
• Employees: 23
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A